NovoCure Limited (NASDAQ:NVCR – Get Free Report) has received an average rating of “Hold” from the eight analysts that are currently covering the firm, MarketBeat reports. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and four have assigned a buy rating to the company. The average 12 month target price among brokerages that have issued a report on the stock in the last year is $26.9286.
A number of research analysts recently commented on the stock. Evercore reiterated an “outperform” rating on shares of NovoCure in a research note on Friday. Wedbush restated a “neutral” rating and set a $18.00 price objective on shares of NovoCure in a report on Thursday, April 16th. HC Wainwright upped their target price on NovoCure from $47.00 to $49.00 and gave the company a “buy” rating in a research report on Thursday, February 26th. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of NovoCure in a research note on Tuesday, April 21st.
Read Our Latest Stock Report on NovoCure
NovoCure Trading Up 9.3%
NovoCure (NASDAQ:NVCR – Get Free Report) last issued its quarterly earnings data on Thursday, April 30th. The medical equipment provider reported ($0.62) earnings per share for the quarter, missing the consensus estimate of ($0.51) by ($0.11). The company had revenue of $174.06 million during the quarter, compared to the consensus estimate of $167.77 million. NovoCure had a negative net margin of 25.66% and a negative return on equity of 50.34%. NovoCure’s revenue for the quarter was up 12.3% compared to the same quarter last year. During the same period in the previous year, the company earned ($0.31) earnings per share. Equities analysts anticipate that NovoCure will post -1.51 EPS for the current year.
Key Headlines Impacting NovoCure
Here are the key news stories impacting NovoCure this week:
- Positive Sentiment: Q1 revenue beat and solid organic growth: Revenue was $174.1M vs. consensus ~$167.8M, up ~12% year‑over‑year — investors are rewarding top‑line strength. Novocure jumps after raising FY26 sales outlook, Q1 revenue beat
- Positive Sentiment: Company raised FY‑2026 sales guidance to $690M–$710M, signaling confidence in demand and recurring treatment adoption (guidance sits around analyst estimates). That outlook upgrade is the primary bullish catalyst. Novocure jumps after raising FY26 sales outlook, Q1 revenue beat
- Neutral Sentiment: Analyst/commentary pieces are highlighting the stock’s breakout potential and explaining the rally — useful for sentiment/context but not new fundamental data. Two medical stocks skyrocket after demolishing views — and one is about to break out
- Neutral Sentiment: Company released the earnings slide deck and full call/transcript — useful for digging into drivers, regional trends and unit economics (see slides/call for color on adoption and margin plans). NovoCure Q1 slide deck NovoCure Limited (NVCR) Q1 2026 Earnings Call Transcript
- Negative Sentiment: EPS missed: GAAP loss of ($0.62) vs. consensus (~$0.51) and wider than last year’s ($0.31) — profitability pressures and higher operating costs remain a concern for profit‑focused investors. NovoCure (NVCR) Reports Q1 Loss, Beats Revenue Estimates
- Negative Sentiment: Company remains unprofitable with negative net margin and ROE; consensus still expects negative EPS for the year — longer path to consistent profitability increases risk if revenue momentum slows. NovoCure: Q1 Earnings Snapshot
Insider Transactions at NovoCure
In other NovoCure news, CEO Frank X. Leonard sold 5,607 shares of the stock in a transaction on Wednesday, March 4th. The stock was sold at an average price of $13.31, for a total transaction of $74,629.17. Following the transaction, the chief executive officer owned 493,793 shares in the company, valued at $6,572,384.83. This trade represents a 1.12% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Uri Weinberg sold 6,412 shares of the business’s stock in a transaction dated Wednesday, March 4th. The shares were sold at an average price of $13.31, for a total transaction of $85,343.72. Following the completion of the sale, the insider directly owned 267,190 shares of the company’s stock, valued at approximately $3,556,298.90. The trade was a 2.34% decrease in their position. The SEC filing for this sale provides additional information. Over the last quarter, insiders sold 140,041 shares of company stock worth $1,860,116. 5.52% of the stock is currently owned by company insiders.
Institutional Inflows and Outflows
A number of institutional investors and hedge funds have recently made changes to their positions in the business. Counterpoint Mutual Funds LLC increased its holdings in shares of NovoCure by 27.9% during the first quarter. Counterpoint Mutual Funds LLC now owns 49,382 shares of the medical equipment provider’s stock worth $538,000 after purchasing an additional 10,777 shares during the period. Strs Ohio boosted its stake in shares of NovoCure by 2.2% in the first quarter. Strs Ohio now owns 59,400 shares of the medical equipment provider’s stock valued at $647,000 after buying an additional 1,300 shares during the period. Pictet Asset Management Holding SA boosted its stake in shares of NovoCure by 23.8% in the first quarter. Pictet Asset Management Holding SA now owns 19,845 shares of the medical equipment provider’s stock valued at $216,000 after buying an additional 3,811 shares during the period. Venturi Wealth Management LLC acquired a new stake in NovoCure during the first quarter worth approximately $123,000. Finally, SG Americas Securities LLC grew its position in NovoCure by 346.7% during the first quarter. SG Americas Securities LLC now owns 1,245,541 shares of the medical equipment provider’s stock worth $13,576,000 after buying an additional 966,735 shares in the last quarter. Institutional investors and hedge funds own 84.61% of the company’s stock.
About NovoCure
NovoCure is a global oncology company pioneering Tumor Treating Fields (TTFields), a novel anti-mitotic therapy for solid tumors. The company’s non-invasive treatment platforms deliver low-intensity, alternating electric fields designed to disrupt cancer cell division. NovoCure’s approach offers an alternative modality to complement existing therapies in oncology, with a focus on hard-to-treat malignancies.
Founded in 2000 and headquartered in Haifa, Israel, NovoCure maintains a second operational center in Portsmouth, New Hampshire.
Recommended Stories
Receive News & Ratings for NovoCure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NovoCure and related companies with MarketBeat.com's FREE daily email newsletter.
